Advanced search
Publication Cover
Acta Oncologica Volume 49, 2010 - Issue 1
Journal homepage
744
Views
12
CrossRef citations to date
0
Altmetric
LETTER TO THE EDITOR

Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours

Ingrid M. E. Desar Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The NetherlandsCorrespondence[email protected]
,
H. Jorn Bovenschen Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
,
Anja J. N. H. Timmer-Bonte Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
,
Mireille V. Cantarini AstraZeneca, Alderley Park, UK
,
Winette T. A. van der Graaf Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
,
Michelle M. van Rossum Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
&
Carla M. L. van Herpen Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
 show all
Pages 113-116 | Received 05 Mar 2009, Accepted 08 Jun 2009, Published online: 26 Jan 2010

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

M Bonny, V Buyse & L Brochez. (2011) DERMATOLOGICAL SIDE EFFECTS OF CURRENT AND UPCOMING TARGETED THERAPIES IN ONCOLOGY. Acta Clinica Belgica 66:2, pages 97-103.
Read now

Articles from other publishers (11)

Chen Peng & Lei Jie-Xin. (2021) The incidence and risk of cutaneous toxicities associated with dabrafenib in melanoma patients: a systematic review and meta-analysis. European Journal of Hospital Pharmacy 28:4, pages 182-189.
Crossref
Victoria Lucia Dávila Osorio, María Asunción Vicente, Eulalia Baselga, Hector Salvador, Ofelia Cruz & Carolina Prat. (2020) Adverse cutaneous effects of mitogen‐activated protein kinase inhibitors in children. Pediatric Dermatology 38:2, pages 420-423.
Crossref
Dylan Haynes & Alex G. Ortega-Loayza. (2020) Adverse cutaneous reactions to chemotherapeutic drugs. Clinics in Dermatology 38:6, pages 712-728.
Crossref
Mai P. Hoang & Daniela Kroshinsky. 2020. Hospital-Based Dermatopathology. Hospital-Based Dermatopathology 757 795 .
A. Chambelland, M.-C. Koeppel, E. Desmedt, J. Fongue, J.-P. Buono, P. Berbis & E. Delaporte. (2019) Éruption nodulo-kystique induite par le sorafénib. Annales de Dermatologie et de Vénéréologie 146:10, pages 646-654.
Crossref
Jonathan J. Lee, Daniela Kroshinsky & Mai P. Hoang. (2017) Cutaneous Reactions to Targeted Therapy. The American Journal of Dermatopathology 39:2, pages 67-82.
Crossref
James B. Macdonald, Brooke Macdonald, Loren E. Golitz, Patricia LoRusso & Aleksandar Sekulic. (2015) Cutaneous adverse effects of targeted therapies. Journal of the American Academy of Dermatology 72:2, pages 221-236.
Crossref
Jonathan L. Curry, Carlos A. Torres-Cabala, Kevin B. Kim, Michael T. Tetzlaff, Madeleine Duvic, Kenneth Y. Tsai, David S. Hong & Victor G. Prieto. (2014) Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. International Journal of Dermatology 53:3, pages 376-384.
Crossref
I. Manousaridis, S. Mavridou, S. Goerdt, M. Leverkus & J. Utikal. (2013) Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management. Journal of the European Academy of Dermatology and Venereology 27:1, pages 11-18.
Crossref
V. Sibaud, J.-P. Delord, C. Chevreau, D. Gangloff & I. Garrido-Stowhas. (2012) Toxicité dermatologique des nouvelles thérapies ciblées anticancéreuses utilisées en oncodermatologie. Annales de Chirurgie Plastique Esthétique 57:2, pages 106-113.
Crossref
Yevgeniy Balagula, Katherine Barth Huston, Klaus J. Busam, Mario E. Lacouture, Paul B. Chapman & Patricia L. Myskowski. (2010) Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Investigational New Drugs 29:5, pages 1114-1121.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.